Skip to content
value.today

Titan Pharmaceuticals Inc.

Total raised
$16 M
4 rounds on record
Latest round
$2 M
Feb 2022
First round on record
Aug 2019
Today
Private
See the company page

Titan Pharmaceuticals Inc. is listed today as Titan Pharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Titan Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2022$2 MNo. 4Under $2 million

Titan Pharmaceuticals Inc.: Raise no. 4, Feb 2022

Investors in this round

1 investor had bought by the notice of Feb 7, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $7 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$106,447
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katherine Beebe DeVarney · Executive Officer, Director
  • Marc Rubin · Executive Officer, Director · Executive Chairman
  • James R. McNab, Jr. · Director
  • Joseph A. Akers · Director
  • M. David McFarlane · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Offering amount represents 1,289,796 Pre-Funded Warrants and 4,664,038 Placement Warrants at a combined purchase price of $1.179 per warrant. Amount sold represents 1,289,796 Pre-Funded warrants.”

Signed by Kate Beebe DeVarney, Ph.D., President and COO. Source: SEC Form D, newest notice filed Feb 7, 2022. Read the notice at the SEC.

optionsSEC
Jan 2021$10 MNo. 3$2 to $10 million

Titan Pharmaceuticals Inc.: Raise no. 3, Jan 2021

Investors in this round

7 investors had bought by the notice of Jan 21, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$677,162
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katherine Beebe DeVarney · Executive Officer, Director
  • Marc Rubin · Executive Officer
  • James R. McNab, Jr. · Director
  • Joseph A. Akers · Director
  • M. David McFarlane · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kate Beebe DeVarney, Ph.D., President and COO. Source: SEC Form D, newest notice filed Jan 21, 2021. Read the notice at the SEC.

optionsSEC
Jan 2020$2 MNo. 2$2 to $10 million

Titan Pharmaceuticals Inc.: Raise no. 2, Jan 2020

Investors in this round

5 investors had bought by the notice of Jan 9, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$152,250
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dane Hallberg · Executive Officer
  • Katherine DeVarney · Executive Officer, Director
  • Marc Rubin · Executive Officer, Director
  • Sunil Bhonsle · Executive Officer, Director
  • James R. McNab, Jr. · Director
  • Joseph A. Akers · Director
  • M. David McFarlane · Director
  • Scott A. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Represents a 7% fee paid pursuant to a placement agency agreement.”
  • On the amounts: “Represents private placement warrants to purchase up to 8,700,000 shares of common stock issued in connection with a concurrent registered direct offering. Total Offering Amount includes the securities sold in such concurrent registered direct offering.”

Signed by Sunil Bhonsle, CEO and President. Source: SEC Form D, newest notice filed Jan 9, 2020. Read the notice at the SEC.

optionsSEC
Aug 2019$2 MNo. 1$2 to $10 million

Titan Pharmaceuticals Inc.: Raise no. 1, Aug 2019

Investors in this round

1 investor had bought by the notice of Aug 19, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$148,786
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dane Hallberg · Executive Officer
  • Katherine Beebe · Executive Officer
  • Marc Rubin · Executive Officer, Director
  • Sunil Bhonsle · Executive Officer, Director
  • James R. McNab, Jr. · Director
  • Joseph A. Akers · Director
  • M. David McFarlane · Director
  • Rajinder A. Kumar · Director
  • Scott A. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Represents a 7% fee paid pursuant to a placement agency agreement.”
  • On the amounts: “Represents private placement warrants to purchase up to 2,852,314 shares of common stock issued in connection with a concurrent registered direct offering. Total Offering Amount includes the securities sold in such concurrent registered direct offering.”

Signed by Sunil Bhonsle, CEO and President. Source: SEC Form D, newest notice filed Aug 19, 2019. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Titan Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2022).

    SEC Form D · Feb 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2022

That is all the official record says: Titan Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Titan Pharmaceuticals Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Titan Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Sire Group Ltd.Companynot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Titan Pharmaceuticals Inc.
NameRoleNamed in
Katherine Beebe DeVarneyExecutive officerFeb 2022
Marc RubinExecutive ChairmanFeb 2022
Dane HallbergExecutive officerJan 2020
Katherine DeVarneyExecutive officerJan 2020
Sunil BhonsleExecutive officerJan 2020
Katherine BeebeExecutive officerAug 2019
James R. McNab, Jr.DirectorFeb 2022
Joseph A. AkersDirectorFeb 2022
Katherine Beebe DeVarneyDirectorFeb 2022
M. David McFarlaneDirectorFeb 2022
Marc RubinExecutive ChairmanFeb 2022
Katherine DeVarneyDirectorJan 2020
Scott A. SmithDirectorJan 2020
Sunil BhonsleDirectorJan 2020
Rajinder A. KumarDirectorAug 2019

About

California company with the stock symbol TTNP.